GlobeNewswire by notified

Wood Mackenzie and Ball Corporation announce satellite data analytics collaboration

Share

Agreement set to accelerate development of advanced analytics for energy markets

EDINBURGH/LONDON/WESTMINSTER, Colo., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Wood Mackenzie, Inc. a Verisk business (NASDAQ:VRSK), and Ball Corporation (NYSE: BLL) announced today that they have signed an agreement between the two organisations to accelerate the development of advanced analytics for energy markets.   

The collaboration will bring together data from the world’s largest private network of in-field monitors - owned by Wood Mackenzie – with satellite data analytics from Ball Aerospace, a business of Ball Corporation, to offer customers a near real-time view of the natural resources sector.

Devin Geoghegan, VP of Innovation and Head of the Innovation & Analytics Lab at Wood Mackenzie, said: “Combining Ball’s geospatial capabilities with Wood Mackenzie’s deep domain energy expertise will provide our customers with near real-time satellite data analytics. Our respective customers increasingly expect and demand access to higher-frequency data, which allows them to track daily developments that affect the short- to medium-term outlooks for commodity markets. In partnership with Ball, we plan to develop a suite of market-leading datasets and analytics products that will provide significant additional value for customers.”

Steve Smith, vice president and general manager, Systems Engineering Solutions, Ball Aerospace said: “Satellite data analytics and domain knowledge have traditionally been separate in our industry. This collaboration with the team at Wood Mackenzie offers an opportunity to extend our expertise in remote sensing and data analytics to new applications. We are excited about the potential benefits for our customers.”

With more than 60 years of experience in remote sensing, data processing and intelligence, Ball Aerospace has spent the last eight years using cutting-edge satellite data analytics and intelligence capabilities to monitor physical world activity within the natural resources sector through Ball’s commercial-facing analytics business.

Wood Mackenzie operates the world’s largest private network of in-field monitors and distributes industry-leading alternative energy data, delivering market intelligence across the commodity and energy spectrum, including power, oil, natural gas, natural gas liquids, agriculture, biofuels, and maritime freight.

- Ends -

Notes to editor:

For further information, please contact:
Anthea Pitt 
+44 330 124 9436 
anthea.pitt@woodmac.com

Media contact: Joanna Climer, (303) 939-7041, jclimer@ball.com; Investor Relations: Ann Scott, (303) 460-3537, ascott@ball.com


About Ball Corporation
Ball Corporation (NYSE: BLL) supplies innovative, sustainable aluminum packaging solutions for beverage, personal care and household products customers, as well as aerospace and other technologies and services primarily for the U.S. government. Ball Corporation and its subsidiaries employ 21,500 people worldwide and reported 2020 net sales of $11.8 billion. For more information, visit www.ball.com, or connect with us on Facebook or Twitter.

About Wood Mackenzie
Wood Mackenzie, a Verisk Analytics business, is a trusted source of commercial intelligence for the world's natural resources sector. We empower clients to make better strategic decisions, providing objective analysis and advice on assets, companies and markets. For more information, visit: www.woodmac.com or follow us on Twitter @WoodMackenzie
WOOD MACKENZIE is a trademark of Wood Mackenzie Limited and is the subject of trademark registrations and/or applications in the European Community, the USA and other countries around the world.

About Verisk
Verisk (Nasdaq:VRSK) provides predictive analytics and decision support solutions to customers in the insurance, energy and specialized markets, and financial services industries. More than 70 percent of the FORTUNE 100 relies on the company’s advanced technologies to manage risks, make better decisions and improve operating efficiency. The company’s analytic solutions address insurance underwriting and claims, fraud, regulatory compliance, natural resources, catastrophes, economic forecasting, geopolitical risks, as well as environmental, social and governance (ESG) matters. Celebrating its 50th anniversary, the company continues to make the world better, safer and stronger, and fosters an inclusive and diverse culture where all team members feel they belong. With more than 100 offices in nearly 35 countries, Verisk consistently earns certification by Great Place to Work. For more: Verisk.comLinkedInTwitterFacebook and YouTube.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Bavarian Nordic dedikerer sig til at påbegynde fase 3-forsøg med RSV-vaccinekandidat og til at styrke sit kapitalgrundlag6.12.2021 07:37:01 CET | pressemeddelelse

Bavarian Nordic vil påbegynde fase 3 med RSV-vaccinekandidat i første halvår af 2022 betinget af en succesfuld kapitalforhøjelseEBITDA forventning for 2021 sænkes en smule, da fase 3 forberedelser intensiveres KØBENHAVN, Danmark, 6. december 2021 – Bavarian Nordic A/S (OMX: BAVA), et fuldt integreret vaccineselskab, offentliggør sin beslutning om at påbegynde et fase 3 klinisk forsøg med RSV-vaccinekandidaten, MVA-BN® RSV. Bavarian Nordic har intention om at finansiere studiet gennem en kapitalforhøjelse på op til 10% af den registrerede aktiekapital. Strategisk opdatering vedrørende RSV-vaccinekandidaten Bavarian Nordic er fortsat dedikeret til visionen om at blive en ledende rendyrket vaccinevirksomhed i 2025, hvilket skal opnås gennem en kombination af organisk vækst og/eller opkøb, og MVA-BN RSV har et lovende potentiale til at medvirke til denne vision. Der eksisterer et betydeligt uopfyldt behov for en RSV-vaccine, da antallet af RSV-forårsagede infektioner er på niveau med influ

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base6.12.2021 07:37:01 CET | Press release

Bavarian Nordic to initiate Phase 3 with RSV vaccine candidate in first half of 2022 subject to a successful equity capital raiseEBITDA expectations for 2021 slightly lowered, as Phase 3 preparations are now being intensified COPENHAGEN, Denmark, December 6, 2021 – Bavarian Nordic A/S (OMX: BAVA) a fully integrated vaccines company, formally announces its commitment to initiate a Phase 3 clinical trial of its RSV vaccine candidate, MVA-BN® RSV. Bavarian Nordic intends to fund the trial through an equity raise, of up to 10% of its registered share capital. Strategic update on RSV vaccine candidate Bavarian Nordic remains committed to the vision of becoming a leading pure-play vaccine company by 2025 through a combination of organic growth and/or acquisitions, and MVA-BN RSV holds the potential to become a key contributor to this vision. There is a significant unmet need for an RSV vaccine, as the number of RSV-induced infections are very similar to influenza and lead to an estimated 177

Intertrust and CSC agree on recommended all-cash offer of EUR 20.00 per share6.12.2021 07:15:00 CET | Press release

JOINT PRESS RELEASE This is a joint press release by Intertrust N.V. ("Intertrust" or the "Company") and Corporation Service Company ("CSC" or the "Offeror") pursuant to the provisions of Section 4, paragraphs 1 and 3, Section 5, paragraph 1 and Section 7, paragraph 4 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the "Decree") in connection with the intended recommended public offer (the "Offer") by the Offeror for all the issued and outstanding ordinary shares in the capital of Intertrust. This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Intertrust. Any offer will be made only by means of an offer memorandum (the "Offer Memorandum") approved by the AFM. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan. Intertrust and CSC agree on recommended all-cash offer of EUR 20

Results of EssilorLuxottica’s mandatory public offer for GrandVision shares6.12.2021 07:00:00 CET | Press release

Results of EssilorLuxottica’s mandatory public offer for GrandVision shares • Acceptance Period ended 3 December 2021 (at 17:40 hours CET) • 13.06% of the Shares have been tendered under the Offer during the Acceptance Period • Including the 86.67% of the Shares already held by the Offeror, the Offeror will hold a total interest of 99.73% • Settlement of the Offer will take place on 8 December 2021, at which date the Offer Price of Euro 28.42 per Share will be paid • Remaining Shares can be tendered during the Post-Acceptance Period, commencing on 7 December 2021 at 09:00 hours CET and ending on 20 December 2021 at 17:40 hours CET Charenton-le-Pont, France and Schiphol, the Netherlands (6 December, 2021 – 7:00am CET) – With reference to the press release of 7 October 2021 by EssilorLuxottica S.A. (the “Offeror“) and GrandVision N.V. (“GrandVision”) regarding the publication of the offer memorandum of the same date (the “Offer Memorandum”) for the recommended mandatory public offer (the

Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections6.12.2021 07:00:00 CET | Press release

The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisionsAffordable and small, instrument-free testing kit enables convenient use for healthcare professionals at different point of care locations and in resource-limited settingsThe test works seamlessly with NAVIFY® Pass, Roche’s digital solution that allows individuals and healthcare professionals to immediately store, display, and share their COVID-19 test results and vaccine status through a unique data matrix Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets accepting the CE Mark by the beginning of January. Roche also intends to file for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) in early 2022. The

Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate5.12.2021 18:21:41 CET | Press release

Bavarian Nordic’s non-adjuvanted COVID-19 vaccine candidate, ABNCoV2 (100μg), demonstrated a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against the Wuhan variant by 2-40-fold depending on the initial levels of antibodiesThe large boosting effect of ABNCoV2 elevated the neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-21A similar fold increase was observed for all SARS-CoV-2 variants tested (Wuhan, Alpha, Beta and Delta) following the booster vaccination with ABNCoV2The vaccine was well-tolerated, with no serious adverse events reportedThese initial results confirm the potential of ABNCoV2 to function as a universal COVID-19 booster vaccineThe Company’s management will host a conference call tomorrow at 2 pm CET (8 am EST) to discuss the results COPENHAGEN, Denmark, December 5, 2021 – Bavarian Nordic A/S (OMX: BAVA), a fully integrated vaccines company, announced today positive topline results f

Bavarian Nordic rapporterer positive toplinjeresultater fra fase 2-forsøg med sin COVID-19 vaccinekandidat5.12.2021 18:21:41 CET | pressemeddelelse

Bavarian Nordics COVID-19 vaccinekandidat uden hjælpestof (adjuvant), ABNCoV2 (100μg), demonstrerede i et fase 2 forsøg en solid boostereffekt, ved at forhøje de eksisterende niveauer af SARS-CoV-2 neutraliserende antistoffer mod Wuhan varianten 2-40 gange afhængigt af de initiale antistofniveauerDen høje boostereffekt af ABNCoV2 forhøjede niveauet af neutraliserende antistoffer til niveauer som er blevet rapporterede som værende yderst effektive (>90%) mod SARS-CoV-21En lignende forhøjelse blev observeret for alle testede SARS-CoV-2 varianter (Wuhan, Alpha, Beta og Delta) efter boostervaccination med ABNCoV2Vaccinen var veltolereret med ingen rapporterede alvorlige bivirkningerDisse toplinjeresultater bekræfter ABNCoV2’s potentiale til at fungere som en universel COVID-19 boostervaccineVirksomhedens ledelse vil afholde en telefonkonference i morgen kl. 14:00 CET for at diskutere resultaterne KØBENHAVN, Danmark, 5. december 2021 – Bavarian Nordic A/S (OMX: BAVA), et fuldt integreret va